All In Biotech

Drug Trial Radar · NCT07449156

A Study to Evaluate Efficacy and Safety of HB0043 in Aadult Patients With Moderate to Severe Acne Vulgaris.

A Phase I, Single-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of HB0043 (Bispecific Antibody Targeting IL-17A and IL-36R) in Adult Patients With Moderate to Severe Acne Vulgaris (AV).

Last checked: Nov 19, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

21

Planned (sponsor's estimate)

Start

Mar 27, 2026

Primary completion

Oct 27, 2026

Study completion Mar 27, 2027

Sponsor

Sponsor type
Industry
Collaborators
Dermatology Hospital affiliated to Shandong First Medical University
First posted
Mar 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Crossover
Masking
Single (care provider)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess efficacy safety and tolerability of HB0043 in adult patients with moderate to severe AV.

Conditions

  • Acne Vulgaris

Interventions

  • HB0043Drug

    300mg

  • PlaceboDrug

    300mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in inflammatory lesion countsTime frame: Week 16
  2. Investigator's global assessment (IGA) - change from BaselineTime frame: Week 16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dermatology Hospital affiliated to Shandong First Medical University,

    Jinan, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.